Peer-reviewed veterinary case report
Bleomycin and IL-12 gene therapy cures some dog oral cancers
By Reed, S D et al.·Published in Cancer gene therapy·2010·Department of Comparative Biomedical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs.
- Species:
- dog
Plain-English summary
A 10-year-old mixed-breed dog with oral squamous cell carcinoma (a type of mouth cancer) was treated with a new therapy called electrochemogenetherapy, which combines a cancer-fighting drug and a special DNA injection with electrical pulses. This treatment completely cured the dog's cancer, and it also showed promising results for other dogs with different types of tumors, although some still had to be euthanized due to metastasis (spread of cancer). The therapy had minimal side effects and helped improve the quality of life for those dogs that didn't fully recover. Overall, this approach appears to be a safe option for treating certain cancers in dogs.
People also search for: dog oral cancer treatment · electrochemogenetherapy for dogs · dog cancer survival rates
Abstract
On the basis of superior outcomes from electrochemogenetherapy (ECGT) compared with electrochemotherapy in mice, we determined the efficacy of ECGT applied to spontaneous canine neoplasms. Intralesional bleomycin (BLM) and feline interleukin-12 DNA injection combined with translesional electroporation resulted in complete cure of two recurrent World Health Organization stage T(2b)N(0)M(0) oral squamous cell carcinomas (SCCs) and one T(2)N(0)M(0) acanthomatous ameloblastoma. Three remaining dogs, which had no other treatment options, had partial responses to ECGT; one had mandibular T(3b)N(2b)M(1) melanoma with pulmonary and lymph node metastases; one had cubital T(3)N(0)M(1) histiocytic sarcoma with spleen metastases; and one had soft palate T(3)N(0)M(0) fibrosarcoma. The melanoma dog had decrease in the size of the primary tumor before recrudescence and euthanasia. The histiocytic sarcoma dog had resolution of the primary tumor, but was euthanized because of metastases 4 months after the only treatment. The dog with T(3)N(0)M(0) fibrosarcoma had tumor regression with recrudescence. Treatment was associated with minimal side effects and was easy to perform, was associated with repair of bone lysis in cured dogs, improved quality of life for dogs with partial responses and extended overall survival time. ECGT seems to be a safe and resulted in complete responses in SCC and acanthomatous ameloblastoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20414325/